Exhibit 10.5
INTELLECTUAL
PROPERTY CROSS-LICENSE AGREEMENT
This
INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this “Agreement”), dated as of July 8, 2024 is made between
MANNKIND CORPORATION, a Delaware corporation company (“MannKind”) and PULMATRIX, INC., a Delaware
corporation (“Pulmatrix”). MannKind and Pulmatrix are each referred to individually as a “Party”
and collectively as the “Parties”.
WHEREAS,
MannKind owns or has valid rights in certain intellectual property and technology (the “MannKind Technology”)
relating to its “Cricket” single-use disposable dry powder inhaler (including any modifications or improvements thereto made
by or on behalf of MannKind, the “Cricket Device”);
WHEREAS,
Pulmatrix has developed an inhaled formulation of dihydroergotamine (“DHE”) for the treatment of acute
migraine known as PUR3100 (“PUR3100”);
WHEREAS,
Pulmatrix owns certain intellectual property and technology for its dry powder delivery technology, iSPERSE (inhaled Small Particles
Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic
applications (including any modifications or improvements thereto made by or on behalf of Pulmatrix, “iSPERSE”);
WHEREAS,
the parties wish to enter into a technology exchange as set forth herein;
WHEREAS,
MannKind desires to grant Pulmatrix the exclusive right to develop, use, manufacture, market, offer and sell the Cricket Device for
the inhaled delivery of DHE in any formulation whatsoever, including PUR31000;
WHEREAS,
MannKind desires to grant Pulmatrix a non-exclusive license to develop, use, manufacture, market, offer and sell the Cricket Device
for the inhaled delivery of one more active pharmaceutical ingredients formulated with iSPERSE for the treatment of neurological disease
in humans (“Neurological Disease”);
WHEREAS,
Pulmatrix desires to grant to MannKind an exclusive license to develop, use, manufacture, market, offer and sell iSPERSE formulations
of Clofazimine;
WHEREAS,
Pulmatrix desires to grant to MannKind an exclusive license to develop, use, manufacture, market, offer and sell formulations of
iSPERSE with one more active pharmaceutical ingredients for the treatment of nontuberculous mycobacteria lung disease in humans (“NTM”);
WHEREAS,
Pulmatrix desires to grant to MannKind an exclusive license to develop, use, manufacture, market, offer and sell iSPERSE formulations
of insulin;
WHEREAS,
Pulmatrix desires to grant to MannKind a non-exclusive license to develop, use, manufacture, market, offer and sell formulations
of iSPERSE with one more active pharmaceutical ingredients for the treatment of endocrine disease in humans (“Endocrine Disease”);
WHEREAS,
Pulmatrix desires to grant to MannKind a non-exclusive license to develop, use, manufacture, market, offer and sell formulations
of iSPERSE with one more active pharmaceutical ingredients for the treatment of interstitial lung diseases (including IPF, PPF and other
related lung diseases) in humans (“ILD”);
WHEREAS,
Pulmatrix has provided to MannKind certain development services related to the development of an iSPERSE formulation of Clofazimine as
specified in a master services agreement dated March 1, 2024 (the “Pulmatrix Services Agreement”); and
WHEREAS,
concurrent with the execution of this Agreement, the Parties are executing (i) that certain Lease Assignment and Assumption Agreement
pursuant to which Pulmatrix will assign to MannKind a specified lease agreement and certain assets related thereto as specified therein
(the “Lease Assignment”) and (ii) that certain Master Services Agreement pursuant to which MannKind will provide
specified development services for Pulmatrix as specified therein (the “MannKind Services Agreement”).
NOW
THEREFORE, in consideration of the ongoing financial and other support provided by the Parties to each other and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, MannKind and Pulmatrix hereby agree as follows:
ARTICLE
1 DEFINITIONS
In
addition to terms defined elsewhere in this Agreement, the following terms shall have the following meanings:
“Affiliate”
means, with respect to a Party, any Person that controls, is controlled by, or is under common control with such Party, where
“control” (including, with correlative meaning, the terms “controlled by” or “under common control with”)
means the possession, directly or indirectly, through one or more intermediaries, of the power to direct or cause the direction of the
management or policies of a Person, whether through ownership of more than fifty percent (50%) of voting securities, controlling interests
or similar arrangement.
“Change
of Control” shall mean, with respect to an Entity (including a Party): (a) the sale or disposition of all or substantially
all of the assets of such Entity or its direct or indirect controlling Affiliate to another Entity, other than to an Entity of which
more than fifty percent (50%) of the voting capital stock are owned after such sale or disposition by shareholders of such Entity or
its direct or indirect controlling Affiliate (in either case, whether directly or indirectly through any parent Entity) or (b) (i) the
acquisition by another Entity, alone or together with any of its Affiliates, other than an employee benefit plan (or related trust) sponsored
or maintained by such Entity or any of its Affiliates, of more than fifty percent (50%) of the outstanding shares of voting capital stock
of such Entity or its direct or indirect controlling Affiliate, or (ii) the acquisition, merger or consolidation of such Entity or its
direct or indirect controlling Affiliate with or into another Entity, other than, in the case of subclause (i) or (ii), an acquisition
or a merger or consolidation of such Entity or its controlling Affiliate in which the holders of shares of voting capital stock of such
Entity or its controlling Affiliate, as the case may be, immediately prior to such acquisition, merger or consolidation will beneficially
own, directly or indirectly, at least fifty percent (50%) of the shares of voting capital stock of the acquiring Entity or the surviving
corporation in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation;
and, in each case ((a) or (b)), whether through a single transaction or a series of related transactions but excluding any and all bona
fide financing transactions.
“Control”
means with respect to any material, Know-How, or intellectual property right, that a Party or its Affiliate (a) owns or (b) has
a license (other than a license granted to such Party under this Agreement) to such material, Know-How, or intellectual property right
and, in each case, has the ability to grant to the other Party access, a license, or a sublicense (as applicable) to the foregoing on
the terms and conditions set forth in this Agreement without violating the terms of any then-existing agreement or other legally enforceable
arrangement with any Third Party. In the event of a Change of Control of a Party, any Know-How, Patents, or other intellectual property
rights that are owned or controlled by a Third Party that becomes an Affiliate of such Party as a result of such Change of Control will
not be deemed to be Controlled by such Party or its Affiliates for purposes of this Agreement.
“Cover”
means, with respect to a claim of a Patent and a product, that such claim would be infringed, absent a license, by the manufacture,
use, offer for sale, sale or importation of such product (considering claims of patent applications to be issued as then pending).
“Effective
Date” means the date that the “Closing” (as defined in the Lease Assignment) has occurred under the Lease Assignment
and the Lease Assignment has gone into effect.
“Entity”
means an individual, corporation, partnership, joint venture, limited liability company, governmental authority, unincorporated
organization, trust, association or other entity.
“Exploit”
means to make, have made, import, use, sell or offer for sale, including to research, develop, commercialize, register, manufacture,
have manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market, sell,
have sold, dispose of, copy, distribute, create derivative works of, publicly perform or publicly display.
“Governmental
Body” means any federal, national, state, provincial, or local government, or political subdivision thereof, or any multinational
organization, or any authority, agency, regulatory body, or commission entitled to exercise any administrative, executive, judicial,
legislative, police, regulatory, or taxing authority or power, or any court or tribunal (or any department, bureau or division of any
of the foregoing, or any governmental arbitrator or arbitral body).
“Know-How”
means any data, results, technology, business or financial information or information of any type whatsoever, in any tangible
or intangible form, including know-how, trade secrets, practices, techniques, methods, processes, designs, manuals, guidelines, inventions,
developments, specifications, formulations, formulae, software, algorithms, marketing reports, expertise, technology, test data (including
pharmacological, biological and chemical, biochemical, clinical test data and data resulting from non-clinical studies), CMC information,
stability data and other study data and procedures.
“Licensed
Technology” means the MannKind Technology and/or the Pulmatrix Technology, as the context may require.
“Licensee”
means the Party receiving rights under a license grant pursuant to this Agreement. Depending on the context, Licensee may mean
either or both of MannKind and Pulmatrix.
“Licensor”
means the Party granting rights under a license grant pursuant to this Agreement. Depending on the context, Licensor may mean
either or both of MannKind and Pulmatrix.
“MannKind
Know-How” means Know-How Controlled by MannKind as of the Effective Date or during the Term that is necessary or reasonably
useful to Exploit the Cricket Device.
“MannKind
Patents” means all Patents Controlled by MannKind as of the Effective Date or during the Term to the extent that such Patents
Cover the Cricket Device. The MannKind Patents existing as of the Effective Date are listed in Schedule 2 attached hereto.
“MannKind
Regulatory Approvals” means all Regulatory Approvals owned by MannKind specifically relating to the Cricket Device.
“MannKind
Technology” means the MannKind Know-How, the MannKind Patents, the MannKind Trademarks and all MannKind Regulatory Approvals.
“MannKind
Trademarks” means any Trademarks used by MannKind to designate the Cricket Device. For clarity, MannKind Trademarks does
not include any Trademarks used to designate MannKind’s or any of its Affiliates’ corporate name(s).
“Patent
Owner” means, with respect to each Patent within the Licensed Technology, the Party that Controls such Patent. In the event
any Patent is owned by both MannKind and Pulmatrix, then for purposes of this Agreement MannKind shall be deemed the Patent Owner of
such Patent.
“Product”
means, (a) with respect to a product Exploited by MannKind, any pharmaceutical product or medical device that incorporates any Pulmatrix
Technology whether alone or in combination with any other active ingredient and (b) with respect to a product Exploited by Pulmatrix,
any pharmaceutical product or medical device that incorporates any MannKind Technology whether alone or in combination with any other
active ingredient.
“Prosecute
and Maintain” means with regard to a Patent, the preparing, filing, prosecuting and maintenance of such Patent, as well
as handling re-examinations and reissues with respect to such Patent, together with the conduct of interferences, the defense of oppositions
and other similar proceedings with respect to the particular Patent. For clarification, Prosecute and Maintain does not include any other
enforcement actions taken with respect to a Patent.
“Pulmatrix
Know-How” means Know-How Controlled by Pulmatrix as of the Effective Date or during the Term that is necessary or reasonably
useful to Exploit iSPERSE.
“Pulmatrix
Patents” means all Patents Controlled by Pulmatrix as of the Effective Date or during the Term that Cover iSPERSE. The
Pulmatrix Patents existing as of the Effective Date are listed in Schedule 1 attached hereto.
“Pulmatrix
Regulatory Approvals” means all Regulatory Approvals owned by Pulmatrix specifically relating to iSPERSE.
“Pulmatrix
Technology” means the Pulmatrix Know-How, the Pulmatrix Patents, the Pulmatrix Trademarks and all Pulmatrix Regulatory
Approvals.
“Pulmatrix
Trademarks” means any Trademark used by Pulmatrix to designate iSPERSE. For clarity, Pulmatrix Trademarks does not include
any Trademarks used to designate Pulmatrix’s or any of its Affiliates’ corporate name(s).
“Regulatory
Approvals” means the technical, medical and scientific licenses, registrations, authorizations and approvals issued by
or under the jurisdiction of a Governmental Body, as necessary for the distribution, marketing, promotion, offer for sale, supply, use,
import, export or sale of a pharmaceutical product or medical device in a regulatory jurisdiction.
“Third
Party” means any entity other than Pulmatrix or MannKind or an Affiliate of either of them.
“Trademark”
means any word, name, symbol, color, shape, designation or device or any combination thereof, including any trademark, service mark,
trade name, trade dress, brand name, product configuration, domain name, logo, design or business symbol, that functions as an identifier
of source, origin or membership, whether or not registered, and all statutory and common law rights therein, and all registrations and
applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.
“Valid
Claim” means (a) a claim of an issued, unexpired Patent that has not been revoked, disclaimed, abandoned or held invalid
or unenforceable by a court or other body of competent jurisdiction in an unappealed or unappealable decision and (b) a claim of any
patent application which has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application.
ARTICLE
2 LICENSE GRANTS
Section
2.1: MannKind Exclusive License Grant to Pulmatrix.
Subject
to the terms and conditions of this Agreement, MannKind hereby grants to Pulmatrix, and Pulmatrix hereby accepts, a worldwide, fully
paid up, royalty-free, exclusive, sub-licensable (through multiple tiers) license to the MannKind Technology in order for Pulmatrix to
Exploit the Cricket Device for the inhaled delivery of DHE in any formulation whatsoever, including PUR31000, for the treatment or prevention
of any disease or condition in humans.
Section
2.2: MannKind Non-Exclusive License Grant to Pulmatrix.
Subject
to the terms and conditions of this Agreement, MannKind hereby grants to Pulmatrix, and Pulmatrix hereby accepts, a worldwide, fully
paid up, royalty-free, non-exclusive, sub-licensable (through multiple tiers) license to the MannKind Technology in order for Pulmatrix
to Exploit the Cricket Device for the inhaled delivery of any dry powder formulation of one more active pharmaceutical ingredients formulated
for the treatment or prevention of Neurological Disease.
Section
2.3: Pulmatrix Exclusive License Grants to MannKind.
(a)
Subject to the terms and conditions of this Agreement, Pulmatrix hereby grants to MannKind, and MannKind hereby accepts, a worldwide,
fully paid up, royalty-free, exclusive, sub-licensable (through multiple tiers) license to the Pulmatrix Technology in order for MannKind
to Exploit formulations of iSPERSE formulation with Clofazimine for inhalation by humans for the treatment or prevention of infection.
(b)
Subject to the terms and conditions of this Agreement, Pulmatrix hereby grants to MannKind, and MannKind hereby accepts, a worldwide,
fully paid up, royalty-free, exclusive, sub-licensable (through multiple tiers) license to the Pulmatrix Technology in order for MannKind
to Exploit formulations of iSPERSE with one more active pharmaceutical ingredients for inhalation for the treatment or prevention of
NTM.
(c)
Subject to the terms and conditions of this Agreement, Pulmatrix hereby grants to MannKind, and MannKind hereby accepts, a worldwide,
fully paid up, royalty-free, exclusive, sub-licensable (through multiple tiers) license to the Pulmatrix Technology in order for MannKind
to Exploit formulations of iSPERSE with insulin for inhalation by humans for the treatment or prevention of diabetes.
Section
2.4: Pulmatrix Non-Exclusive License Grants to MannKind.
(a)
Subject to the terms and conditions of this Agreement, Pulmatrix hereby grants to MannKind, and MannKind hereby accepts, a worldwide,
fully paid up, royalty-free, non-exclusive, sub-licensable (through multiple tiers) license to the Pulmatrix Technology in order for
MannKind to Exploit formulations of iSPERSE with one or more active pharmaceutical ingredients for inhalation for the treatment or prevention
of Endocrine Disease.
(b)
Subject to the terms and conditions of this Agreement, Pulmatrix hereby grants to MannKind, and MannKind hereby accepts, a worldwide,
fully paid up, royalty-free, non-exclusive, sub-licensable (through multiple tiers) license to the Pulmatrix Technology in order for
MannKind to Exploit formulations of iSPERSE with one or more active pharmaceutical ingredients for inhalation for the treatment or prevention
of ILD.
Section
2.5: No Implied Licenses; Negative Covenant.
Except
as otherwise specifically set forth herein, only the licenses granted pursuant to the express terms of this Agreement shall be of any
legal force and effect. No license or other intellectual property rights shall be created by implication in any Patents, technology and/or
proprietary information owned by a Party, even if such Patents, technology, or proprietary information is necessary to exploit the Licensed
Technology. Neither Party shall, and neither Party shall permit any of its Affiliates or sublicensees to, practice any Licensed Technology
licensed to it by the other Party outside the scope of the licenses granted to it under this Agreement.
Section
2.6: Scope
(a)
For the avoidance of doubt, the foregoing licenses set forth in this Article 2 are royalty free and not limited by territory.
(b)
The licenses set forth in this Article 2 to Pulmatrix do not include the right for Pulmatrix to manufacture or have manufactured
the Cricket Device.
(c)
The licenses set forth in this Article 2 to Pulmatrix do not include rights to any Know-How, Patents or other rights covering
any active ingredient, formulation technology or other proprietary product other than the Cricket Device itself.
(d)
The licenses set forth in this Article 2 shall not include rights to any Know-How, Patents or other intellectual property rights
in-licensed or acquired by Licensor from a Third Party after the Effective Date unless the applicable Licensee agrees in writing (i)
to be bound by the terms and conditions of any applicable Third Party agreement granting Licensor Control of such Know-How, Patents or
other intellectual property rights and (ii) to pay all payments owed to such Third Party that are attributable to Licensee’s use
of such Know-How, Patents or other intellectual property rights under this Agreement.
Section
2.7 Sublicenses.
Subject
to the terms and conditions of this Agreement, each Party may grant sublicenses through multiple tiers, under any or all of the rights
granted in Section 2.1, Section 2.2, Section 2.3 and Section 2.4, as applicable, to its Affiliates and to
Third Parties (each such Affiliate or Third Party, a “Sublicensee” and each such agreement, a “Sublicense”).
Each Sublicense shall be consistent with the terms and conditions of this Agreement applicable to the scope of the sublicense granted
to such Sublicensee. Each Party shall promptly notify the other Party in writing of any Sublicense granted to a Third Party (other than
non-exclusive Sublicenses granted to Third Party service providers or vendors providing services on such Party’s behalf) and shall
provide the other Party with a copy of such Sublicense; provided, that such Party may redact any confidential or financial information
contained therein that is unnecessary for the other Party to confirm compliance with this Agreement.
Section
2.8 Trademarks.
(a)
MannKind Trademarks. The licenses set forth in this Article 2 to Pulmatrix include the right for Pulmatrix to use the MannKind
Trademarks solely in connection with the Exploitation of Products within the scope of the licenses granted to Pulmatrix under this Article
2. Pulmatrix shall, and shall ensure that its Affiliates and Sublicensees will not, adapt or make any use of any Trademark that is confusingly
similar to any MannKind Trademark or any Trademark that MannKind or its Affiliates use to designate its corporate name. All use of the
MannKind Trademarks shall be consistent with the MannKind Trademark style and usage provisions as identified by MannKind to Pulmatrix
in writing. All goodwill generated from the use of the MannKind Trademarks shall inure to the benefit of and is hereby assigned to MannKind.
MannKind shall have the sole right to prosecute, enforce and defend the MannKind Trademarks.
(b)
Pulmatrix Trademarks. The licenses set forth in this Article 2 to MannKind include the right for MannKind to use the Pulmatrix
Trademarks solely in connection with the Exploitation of Products within the scope of the licenses granted to MannKind under this Article
2. MannKind shall, and shall ensure that its Affiliates and Sublicensees will not, adapt or make any use of any Trademark that is confusingly
similar to any Pulmatrix Trademark or any Trademark that Pulmatrix or its Affiliates use to designate its corporate name. All use of
the Pulmatrix Trademarks shall be consistent with the Pulmatrix Trademark style and usage provisions as identified by Pulmatrix to MannKind
in writing. All goodwill generated from the use of the Pulmatrix Trademarks shall inure to the benefit of and is hereby assigned to Pulmatrix.
Pulmatrix shall have the sole right to prosecute, enforce and defend the Pulmatrix Trademarks.
Section
2.9 Technology Transfer.
(a)
Transfer to MannKind. Within thirty (30) days after the Effective Date, Pulmatrix shall provide MannKind with the Pulmatrix Know-How
and all regulatory materials (including Regulatory Approvals) specifically relating to iSPERSE. On an ongoing basis thereafter, at the
reasonable request of MannKind, Pulmatrix shall provide MannKind with copies of any Pulmatrix Know-How generated since the last such
transfer under this Section 2.8.
(b)
Transfer to Pulmatrix. Within thirty (30) days after the Effective Date, MannKind shall provide Pulmatrix with the MannKind Know-How
and all regulatory materials (including Regulatory Approvals) specifically relating to the Cricket Device. On an ongoing basis thereafter,
at the reasonable request of Pulmatrix, MannKind shall provide Pulmatrix with copies of any MannKind Know-How generated since the last
such transfer under this Section 2.8.
ARTICLE
3 PATENT PROSECUTION AND MAINTENANCE; PATENT ENFORCEMENT
Section
3.1: Patent Prosecution and Maintenance.
Each
Party, as Patent Owner, shall have the first right to Prosecute and Maintain any and all Patents Controlled by such Party that are included
in such Party’s Licensed Technology, at its own cost. If a Patent Owner decides not to: (i) prosecute certain patent applications
within the Licensed Technology to issuance or (ii) maintain any United States or foreign issued Patent within the Licensed Technology,
the Patent Owner shall timely notify the Licensee of such Patent in writing thereof and solely to the extent the Patent Owner owns such
Patent, upon written request by the Licensee, the Parties shall cooperate to transfer the ownership of such Patent to the Licensee, provided,
that the Patent Owner shall retain a worldwide, irrevocable, perpetual, fully paid up, royalty-free, exclusive, transferable, sublicensable
(through multiple tiers) license to and under the transferred Patent in any field of use. The preceding sentence shall not apply to any
patent applications within the Licensed Technology that will be abandoned for the pursuit of a utility application in the case of a provisional
application, a divisional or continuation application in the case of any utility application, any national stage applications in the
case of a Patent Cooperation Treaty (PCT) application, or countries not validated in the case of a European or other regional patent
application. Before any Party makes a filing or extension on any Patent included in such Party’s Licensed Technology, the Patent
Owner shall consider in good faith any reasonable comments thereto provided by the other Party in connection with the prosecution of
such Patents. Pulmatrix shall promptly provide MannKind with copies of all material communications from any patent authority regarding
the Pulmatrix Patents, and shall provide MannKind, for its review and comment, with drafts of any material filings or responses to be
made to such patent authorities in a reasonable amount of time in advance of submitting such filings or responses.
Section
3.2: Infringement Procedures.
During
the term of this Agreement, each Party shall promptly inform the other of any suspected infringement, misuse, misappropriation, theft
or breach of confidence of other proprietary rights in the Licensed Technology by a Third Party in the other Party’s exclusive
field of use as provided in Article 2 (collectively “Third Party Activities”), and with respect to such activities
as are suspected. MannKind shall have the sole right, but not the obligation, to institute an action or proceeding against Third Party
Activities related to the MannKind Patents and to defend any declaratory judgment action relating to the MannKind Patents. For Third
Party Activities involving the Pulmatrix Patents in MannKind’s exclusive field of use as provided in Article 2, MannKind shall
have the sole right, but not the obligation, to institute an action or proceeding against Third Party Activities and defend any declaratory
judgment action relating thereto and Pulmatrix shall have the right, but not the obligation, to join any such suit, legal action or proceeding
that is initiated by MannKind with respect to the Pulmatrix Patents, at MannKind’s cost. Pulmatrix shall, where necessary, furnish
a power of attorney solely for such purpose, or be named as a necessary party, to such action, at MannKind’s cost. Pulmatrix will
reasonably cooperate with MannKind in such action. In addition, notwithstanding anything to the contrary contained herein, if Pulmatrix
cooperates in such action, such cooperation shall be at MannKind’s sole expense. All recoveries, whether by judgment, award, decree
or settlement, from infringement or misuse of Licensed Technology under this Section 3.2 shall be apportioned as follows: (a)
MannKind shall recover an amount equal the costs and expenses incurred by MannKind directly related to the prosecution of such action
or proceeding and Pulmatrix shall recover any unreimbursed costs and expenses incurred by Pulmatrix, if any, directly related to its
cooperation in the prosecution of such action or proceeding (which amounts shall be allocated pro rata if insufficient to cover the totality
of such costs and expenses) and (b) the remainder shall be allocated to the Party bringing the action.
Section
3.3: Consent to Settle.
A
settlement, consent judgment or other voluntary final disposition of an action covered by an action covered by Section 3.2 may
be entered into by the party instituting such action without the consent of the non-enforcing Party; provided, however, that any such
settlement, consent judgment or other disposition shall not, without the prior written consent of the non-enforcing Party, (a) impose
any liability or obligation on the non-enforcing Party or any of its Affiliates, or (b) admit the invalidity or unenforceability of,
or otherwise impair or materially adversely affect the scope of, any Patent owned or controlled by the non-enforcing Party, such consent
to not be unreasonably withheld, conditioned or delayed.
Section
3.4: Defense of Infringement Claims.
If
any Third Party asserts a claim, demand, action, suit or proceeding against a Licensee (or any of its sublicensees), alleging that the
use or practice of the Licensed Technology, infringes, misappropriates or violates the intellectual property rights of any Person (any
such claim, demand, action, suit or proceeding being referred to as an “Infringement Claim”), the Licensee
shall promptly notify the Patent Owner in writing specifying the facts, to the extent known, in reasonable detail. In the case of any
such Infringement Claim, the Licensee shall assume control of the defense and shall have the exclusive right to settle any Infringement
Claim against the Licensee without the consent of the Patent Owner; provided, however, if such settlement requires any payment from the
Patent Owner, imposes any obligation or liability on the Patent Owner or decreases the Patent Owner’s rights or interests under
this Agreement, the Licensee shall be required to obtain the Patent Owner’s consent, which consent will not be unreasonably withheld.
ARTICLE
4 TERM; TERMINATION
Section
4.1: Term. This Agreement shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article 4,
shall expire, on a country-by-country basis, on the date of expiration of the last Valid Claim of the Patents in the Licensed Technology.
Upon the expiration of the Term for a particular country, the licenses granted under Section 2.1 with respect to such country
shall become perpetual and irrevocable. If the Effective Date has not occurred by July 31, 2024, then this Agreement shall be void ab
initio as if it was never executed by the parties.
Section
4.2: Termination for Breach. If either Party believes that the other is in breach of its material obligations hereunder, then the
non-breaching Party may deliver notice of such breach to the other Party. For all breaches other than a failure to make a payment as
set forth in this Agreement, the allegedly breaching Party shall have sixty (60) days from such notice to dispute or cure such breach.
If the Party receiving notice of breach fails to cure, or fails to dispute, that breach within the applicable period set forth above,
then the Party originally delivering the notice of breach may terminate this Agreement effective on written notice of termination to
the other Party.
Section
4.3: Termination for Bankruptcy. Either Party may terminate this Agreement in its entirety upon written notice to the other Party
in the event that (a) a case is commenced by or against such other Party under applicable bankruptcy, insolvency or similar laws, which
case, if commenced against (not by) such other Party, is not dismissed within ninety (90) days of the commencement thereof, (b) such
other Party files for bankruptcy, reorganization, liquidation, receivership or similar proceedings, (c) such other Party assigns all
or a substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for such other Party’s
business, (e) a substantial portion of such other Party’s business is subject to attachment or similar process or (f) anything
analogous to any of the events described in the foregoing clauses (a) through (f) occurs under the laws of any applicable jurisdiction.
Section
4.4: Effects of Termination.
(a)
Termination by MannKind. Upon termination of this Agreement by MannKind pursuant to Section 4.2 or Section 4.3:
(i) all rights and licenses granted by MannKind to Pulmatrix under this Agreement shall terminate and revert to MannKind, (ii) all rights
and licenses granted by Pulmatrix to MannKind under this Agreement shall survive and become perpetual and irrevocable, and (iii) at the
request of MannKind, Pulmatrix shall return, or at the election of MannKind, destroy, and thereafter provide MannKind with written certification
evidencing such destruction, all data, files, records and other materials in its or its Affiliates’ or Sublicensees’, possession
or control containing or comprising MannKind’s Confidential Information; provided, that Pulmatrix shall be entitled to retain one
(1) copy MannKind’s Confidential Information solely for litigation or archival purposes and Pulmatrix shall not be required to
delete any of MannKind’s Confidential Information that is stored automatically, such as through server backup processes.
(b)
Termination by Pulmatrix. Upon termination of this Agreement by Pulmatrix pursuant to Section 4.2 or Section 4.3:
(i) all rights and licenses granted by Pulmatrix to MannKind under this Agreement shall terminate and revert to Pulmatrix, (ii) all rights
and licenses granted by MannKind to Pulmatrix under this Agreement shall survive and become perpetual and irrevocable, and (iii) at the
request of Pulmatrix, MannKind shall return, or at the election of Pulmatrix, destroy, and thereafter provide Pulmatrix with written
certification evidencing such destruction, all data, files, records and other materials in its or its Affiliates’ or Sublicensees’,
possession or control containing or comprising Pulmatrix’s Confidential Information; provided, that MannKind shall be entitled
to retain one (1) copy Pulmatrix’s Confidential Information solely for litigation or archival purposes and MannKind shall not be
required to delete any of Pulmatrix’s Confidential Information that is stored automatically, such as through server backup processes.
ARTICLE
5 INDEMNIFICATION
Section
5.1: Pulmatrix Indemnity.
Pulmatrix
shall indemnify, defend, and hold harmless MannKind and its Affiliates and their respective officers, shareholders, members, managers,
directors, employees, personnel and agents (the “MannKind Indemnitees”) from and against all damages or other
amounts payable to a Third Party claimant (including liabilities, costs, expenses, reasonable attorneys’ fees, damages and losses
resulting from the foregoing) (collectively, “Losses”) resulting from any claims, actions, causes of action
or demands, brought by or on behalf of a Third Party (collectively, “Claims”) arising out of or in connection
with: (a) any breach of any of Pulmatrix’s representations, warranties, covenants, and obligations under this Agreement, (b) any
violation of applicable law by Pulmatrix, its Affiliates or its sublicensees; (c) infringement of intellectual property rights of a Third
Party arising from Pulmatrix’s use of the MannKind Technology; (d) the development, commercialization, marketing or sale of any
Product by Pulmatrix, its Affiliates and Sublicensees, and (e) Pulmatrix’s, its Affiliates’ or its Sublicensees’ gross
negligence, willful misconduct or fraudulent conduct. Pulmatrix shall not be responsible to, nor shall it indemnify, defend or hold harmless
MannKind for any Claims to the extent arising from any negligent act or omission or willful misconduct of any MannKind Indemnitee or
a Claim for which MannKind would be required to indemnify Pulmatrix under this Agreement. This Section 5.1 shall survive any termination
or expiration of this Agreement.
Section
5.2: MannKind Indemnity.
MannKind
shall indemnify, defend, and hold harmless Pulmatrix and its Affiliates and their respective officers, shareholders, members, managers,
directors, employees, personnel and agents (the “Pulmatrix Indemnitees”) from and against all Losses resulting
from any Third Party Claims arising out of or in connection with: (a) any breach of any of MannKind’s representations, warranties,
covenants, and obligations under this Agreement, (b) any violation of applicable law by MannKind, its Affiliates or its sublicensees;
(c) any Third Party claim of infringement of intellectual property rights of such Third Party arising from MannKind’s use of the
Pulmatrix Technology; (d) the development, commercialization, marketing or sale of any Product by or on behalf of MannKind, its Affiliates
or Sublicensees; and (e) MannKind’s, its Affiliates or its Sublicensees gross negligence, willful misconduct or fraudulent conduct.
MannKind shall not be responsible to, nor shall it indemnify, defend or hold harmless Pulmatrix for any Claims to the extent arising
from any negligent act or omission or willful misconduct of any Pulmatrix Indemnitee or a Claim for which Pulmatrix would be required
to indemnify MannKind under this Agreement. This Section 5.2 shall survive any termination or expiration of this Agreement.
Section
5.3: Procedure.
The
indemnified Party shall promptly notify the indemnifying Party in writing of any Claim for which it believes it is entitled to indemnification
hereunder. Failure or delay in providing such notice shall not relieve the indemnifying Party of its indemnification obligations, except
to the extent the indemnifying Party demonstrates that the defense or settlement of the Claim has been prejudiced thereby. Subject to
the provisions below in this Section 5.3, the indemnifying Party shall have the right to control the defense and settlement of
any Claim, or may at any time tender control of the defense or settlement of such Claim to the indemnified Party. The indemnified Party
may, at its own cost, elect to participate in the defense or settlement of any Claim with counsel of its choice. No compromise or settlement
may be committed to by the indemnifying Party without the indemnified Party’s prior written approval (which shall not be unreasonably
withheld, conditioned or delayed).
ARTICLE
6 LIMITATION OF LIABILITY
Section
6.1: WAIVER OF CONSEQUENTIAL DAMAGES.
EXCEPT
FOR BREACHES OF ARTICLE 7, IN NO EVENT SHALL EITHER PARTY, ITS DIRECT OR INDIRECT SUBSIDIARIES, AFFILIATES, DIRECTORS, OFFICERS, AGENTS,
EMPLOYEES OR REPRESENTATIVES BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES OF ANY KIND,
NOR FOR ANY LOST PROFITS OR REVENUES, IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, EXCEPT TO THE EXTENT THAT A PARTY IS LIABLE
TO A THIRD PARTY FOR THE SAME IN CONNECTION WITH A CLAIM FOR WHICH SUCH PARTY IS ENTITLED TO INDEMNIFICATION UNDER ARTICLE 5.
Section
6.2: LIMITATION OF LIABILITY.
EXCEPT
FOR BREACHES OF ARTICLE 7 OR DAMAGES AVAILABLE TO A THIRD PARTY IN CONNECTION WITH A CLAIM FOR WHICH SUCH PARTY IS ENTITLED TO INDEMNIFICATION
UNDER ARTICLE 5, THE MAXIMUM AGGREGATE LIABILITY OF EITHER PARTY TO THE OTHER, FOR ANY REASON AND UPON ANY CAUSE OF ACTION ARISING OUT
OF OR RELATING TO THIS AGREEMENT SHALL BE LIMITED TO AN AMOUNT NOT TO EXCEED $1,000,000, EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES OR SUCH DAMAGES ARE REASONABLY FORESEEABLE. THE FOREGOING LIMITATIONS SHALL APPLY REGARDLESS OF THE CAUSE OR FORM OF
ACTION, WHETHER BASED IN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, WARRANTY OR OTHERWISE AND SHALL NEVER BE DEEMED TO FAIL IN THEIR
ESSENTIAL PURPOSE.
Section
6.3: Insurance.
Each
Party shall procure and maintain insurance, including product liability insurance, with respect to its activities hereunder that is consistent
with normal business practices of prudent companies similarly situated at all times during which any product subject to a license granted
to such Party under this Agreement is being clinically tested in human subjects or commercially distributed or sold. Each Party shall
provide the other Party with evidence of such insurance upon request and shall provide the other Party with written notice at least sixty
(60) days prior to the cancellation, non-renewal or material decrease in such insurance. Such insurance shall not be construed to create
a limit of either Party’s liability with respect to its indemnification obligations under Article 5.
ARTICLE
7 CONFIDENTIALITY
Section
7.1: Definition of Confidentiality.
For
purposes of this Agreement, “Confidential Information” of a Party means any non-public information or materials
belonging to, concerning or in the possession or control of such Party or its Affiliates (the “Disclosing Party”) that
is furnished, disclosed or otherwise made available (directly or indirectly) to the other Party (or Persons acting on such other Party’s
behalf) (the “Receiving Party”) in connection with this Agreement and which is either marked or identified
as confidential or proprietary or is of a type that a reasonable person would recognize it to be confidential or proprietary.
Section
7.2: Confidentiality Obligations.
The
Receiving Party shall: (a) hold the Confidential Information in strict confidence and avoid the disclosure thereof to any Third Party
by using the same degree of care as it uses to avoid the unauthorized use or disclosure of its own Confidential Information of a similar
nature, but not less than reasonable care; and (b) not use the Confidential Information for any purpose except as contemplated under
this Agreement. Should a Party become possessed of a trade secret of a Disclosing Party under the terms of this Agreement, the Receiving
Party shall not, during the term and thereafter, disclose such trade secret to a Third Party. The Receiving Party shall restrict the
possession and use of Confidential Information to its employees, agents, consultants, contractors, personnel, Affiliates and Sublicensees
who have a need to know and are bound by confidentiality obligations no less stringent than those contained herein. The Receiving Party
may disclose Confidential Information as required by applicable law, provided the Receiving Party discloses only such information as
is required by applicable law and, if permitted by applicable law, uses reasonable efforts to notify the Disclosing Party of such disclosure
and provides reasonable assistance to the Disclosing Party in seeking a protective order or similar confidential treatment at Disclosing
Party’s expense. The Receiving Party shall promptly notify the Disclosing Party of any facts known to the Receiving Party regarding
any unauthorized disclosure or use of Confidential Information. Each Party acknowledges that its breach of the obligations set forth
in this Section 7.2 may cause irreparable harm for which the other Party shall be entitled to seek injunctive or other equitable
relief. All Confidential Information shall remain the exclusive property of the Disclosing Party.
Section
7.3: Limitations.
Confidential
Information shall not include any information to the extent that such information: (a) was demonstrably known by the Receiving Party
before disclosure by the Disclosing Party, (b) becomes generally publicly known other than through any act or omission of the receiving
Party in breach of this Agreement, (c) was disclosed to the Receiving Party free of any obligation of confidentiality by a Third Party
who has a legal right to make such disclosure; or (d) is independently developed by the Receiving Party by persons without access to
such information.
Section
7.4: Residual Rights.
Each
Party acknowledges and agrees that the other Party, its Affiliates and their respective employees and agents shall be free to use and
employ their general skills, ideas, concepts, know-how and expertise, and to use, disclose, and employ any generalized ideas, concepts,
know-how, methods, techniques or skills gained or learned during the course of any activities performed hereunder, subject to its obligations
respecting the other Party’s Confidential Information pursuant to this Article 7. Each Party acknowledges and agrees that
to the extent any former employee of one Party becomes an employee of the other Party, such employee shall be free to use Confidential
Information of such Party that was its former employer within the scope of the licenses granted under this Agreement to the Party that
it is current employer.
Section
7.5: Terms of the Agreement.
(a)
The Parties agree that the material terms of this Agreement are the Confidential Information of both Parties, subject to the special
authorized disclosure provisions set forth in this Section 7.5 or Section 7.2. In addition, a Party may disclose such terms
to the extent reasonably necessary to be disclosed to any bona fide potential or actual investor, acquiror, licensee or merger partner
for the sole purpose of evaluating an actual or potential investment, acquisition, license or merger; provided that in connection with
such disclosure, such Party shall inform each disclosee of the confidential nature of such Confidential Information and ensure that each
such disclosee is contractually obligated to treat such Confidential Information as confidential.
(b)
The Parties acknowledge that either or both Parties may be obligated to file under applicable laws a copy of this Agreement with the
U.S. Securities and Exchange Commission or other Governmental Body. Each Party shall be entitled to make such a required filing, provided
that it requests confidential treatment of the commercial terms and sensitive technical terms hereof and thereof to the extent such confidential
treatment is reasonably available to such Party. In the event of any such filing, each Party will provide the other Party with a copy
of this Agreement marked to show provisions for which such Party intends to seek confidential treatment and shall reasonably consider
and incorporate the other Party’s reasonable comments thereon to the extent consistent with the legal requirements, with respect
to the filing Party, governing disclosure of material agreements and material information that must be publicly filed. Each Party shall
have the right to repeat disclosure any information that has already been publicly disclosed by such Party in accordance with this Section
7.5 without the obligation to repeat this process under this Section 7.5, provided such information remains accurate as of
such time of repeated disclosure.
ARTICLE
8 REPRESENTATIONS AND WARRANTIES AND OTHER AGREEMENTS
Section
8.1: Mutual Representations and Warranties.
Each
Party represents and warrants to the other Party as of the Effective Date that such first Party has: (a) all requisite legal and corporate
power to execute and deliver this Agreement; (b) taken all corporate action necessary for the authorization, execution and delivery of
this Agreement; (c) no agreement or understanding with any Third Party that interferes with or will interfere with the performance of
their respective obligations under this Agreement; (d) obtained and shall maintain all rights, approvals and consents necessary to perform
their respective obligations under this Agreement; (e) taken all action required or necessary to make such agreements legal, valid and
binding obligations upon them; and (f) it has the right to grant the licenses to the other which are granted in this Agreement and it
has not granted any license, option, right or interest in, to or under its Licensed Technology to any Third Party that is inconsistent
with the license granted to the other Party under this Agreement. Each Party further represents and warrants to the other Party as of
the Effective Date that, to its knowledge, none of its Licensed Technology infringes on the rights of any Third Party. MannKind further
represents and warrants to Pulmatrix as of the Effective Date that (x) all of the Patents and Know-How controlled by MannKind that are
necessary or reasonably useful to Exploit the Cricket Device in the fields of use licensed to Pulmatrix under Article 2 are owned by
MannKind and not in-licensed from a Third Party and (y) all of the Patents owned by MannKind that are necessary or reasonably useful
to Exploit the Cricket Device in the fields of use licensed to Pulmatrix under Article 2 are set forth on Schedule 2. Pulmatrix
further represents and warrants to MannKind as of the Effective Date that (1) all of the Patents and Know-How controlled by Pulmatrix
that are necessary or reasonably useful to Exploit iSPERSE in the fields of use licensed to MannKind under Article 2 are owned by Pulmatrix
and not in-licensed from a Third Party and (2) all of the Patents owned by Pulmatrix that are necessary or reasonably useful to Exploit
iSPERSE in the fields of use licensed to MannKind pursuant to Article 2 are set forth on Schedule 1.
Section
8.2: Disclaimer.
NEITHER
PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, WHETHER EXPRESS OR IMPLIED, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY
SET FORTH IN SECTION 8.1, AND EACH PARTY EXPRESSLY DISCLAIMS ANY IMPLIED OR STATUTORY WARRANTIES OF MERCHANTABILITY, FITNESS FOR
A PARTICULAR PURPOSE, QUALITY, TITLE OR ANY REPRESENTATION OR WARRANTY ARISING FROM COURSE OF PERFORMANCE, COURSE OF DEALING OR USAGE
OF TRADE.
Section
8.3 Other Agreements.
(a)
Regulatory Assistance.
(i)
Pulmatrix shall, at MannKind’s request and expense, provide reasonable assistance with respect to regulatory matters concerning
the Exploitation of iSPERSE by or on behalf of MannKind or its Sublicensees within the scope of MannKind’s licenses under this
Agreement, including (x) assistance with respect to regulatory filings required to obtain or maintain Regulatory Approval for MannKind’s
or its Sublicensees’ Products and (y) providing MannKind with regulatory materials in its possession or control that are necessary
or reasonably useful for MannKind to obtain or maintain Regulatory Approval for MannKind’s or its Sublicensees’ Products.
(ii)
MannKind shall, at Pulmatrix’s request and expense, provide reasonable assistance with respect to regulatory matters concerning
the Exploitation of the Cricket Device by or on behalf of Pulmatrix or its Sublicensees within the scope of Pulmatrix’s licenses
under this Agreement, including (x) assistance with respect to regulatory filings required to obtain or maintain Regulatory Approval
for Pulmatrix’s or its Sublicensees’ Products and (y) providing Pulmatrix with regulatory materials in its Control that are
necessary or reasonably useful for Pulmatrix to obtain or maintain Regulatory Approval for Pulmatrix’s or its Sublicensees’
Products.
(b)
Remedial Actions. Each Party will notify the other Party immediately, and promptly confirm such notice in writing, if it obtains
information indicating that any Product being Exploited by such Party may be subject to any recall, market withdrawal, clinical hold,
or any other similar corrective or other regulatory action with respect to such Product taken by virtue of applicable law (a “Remedial
Action”). The Parties will reasonably assist each other in gathering and evaluating such information as is necessary to determine
the necessity of conducting a Remedial Action and preparing and maintaining corresponding documentation, as well as, if necessary, making
any required submissions to the applicable Governmental Body. The Party Exploiting such Product subject to the Remedial Action shall
be solely responsible for all costs and expenses associated with such Remedial Action.
(c)
Regulatory Approvals. Each Party shall have the right to apply for and maintain, at its own cost and expense, all regulatory approvals
of the Products being developed by such Party. Subject to Section 8.3(a), each Party shall be responsible for and have sole discretion
over the preparation of all regulatory materials and all communications and interactions with the applicable regulatory authorities or
other Governmental Bodies with respect to the Products being developed by such Party, both prior to and subsequent to Regulatory Approval.
(d)
Manufacture and Supply.
(i)
At the request of Pulmatrix, the Parties agree to promptly negotiate in good faith and enter into supply agreements for the clinical
and commercial supply of the Cricket Device to Pulmatrix.
(ii)
Without limiting the generality of Section 2.9, at the request of MannKind, Pulmatrix will (x) transfer to MannKind all Know-How
and materials related to manufacturing using iSPERSE (including all CMC related information) as necessary or reasonably useful to enable
MannKind or its Third Party contract manufacturer to manufacture using iSPERSE and (y) provide MannKind with reasonable technical assistance
and support at MannKind’s reasonable cost and expense with respect to manufacturing using iSPERSE.
(e)
Pulmatrix Licensed Technology Transaction Notice. If, during the Term, Pulmatrix or any of its Affiliates determines to initiate
or otherwise engages in discussions with a Third Party (other than Teva Pharmaceutical Industries Ltd) regarding the assignment, transfer
or sale of Pulmatrix’s or its Affiliate’s right, title and interest in and to all or substantially all of the Pulmatrix Licensed
Technology, then Pulmatrix shall provide notice thereof to MannKind. At the request of MannKind after receipt of any such notice, (i)
Pulmatrix will, on a non-exclusive basis (unless otherwise agreed to by the Parties), engage in good faith negotiations with MannKind
regarding such potential assignment, transfer or sale and (ii) Pulmatrix will provide MannKind with a high-level summary of data, results,
and other material information that is relevant to the Pulmatrix Licensed Technology.
(f)
Ownership of Inventions. As between the Parties, each Party shall own all right, title and interest in and to all inventions and
intellectual property rights made solely by or on behalf of its or its Affiliates’ employees, agents, or independent contractors
in exercising its rights under this Agreement.
(g)
Project Technology. Notwithstanding anything to the contrary under the Pulmatrix Services Agreement, Pulmatrix hereby assigns
and transfers to MannKind all of its right, title and interest in and to Project Technology (as such term is defined in the Pulmatrix
Services Agreement) generated by or on behalf of Pulmatrix in performance of the services under the Pulmatrix Services Agreement and
Pulmatrix agrees to take, and to cause its employees, agents, and consultants to take, all further acts reasonably required to evidence
such assignment and transfer to MannKind, at MannKind’s reasonable expense.
ARTICLE
9 ADDITIONAL PROVISIONS
Section
9.1: Further Assurances.
Each
Party covenants and agrees to execute and deliver or cause to be executed and delivered to the other Party such instruments or further
assurances as may, in the reasonable opinion of such other Party, be necessary or desirable to give effect to the provisions of this
Agreement.
Section
9.2: Notices.
All
notices required or permitted under this Agreement shall be in writing and delivered via overnight mail or overnight courier service,
signature proof of receipt required. Notices shall be directed to the addresses set forth below and shall be deemed effective upon receipt.
Either Party may change its address for notices from time to time by providing written notice to the other Party.
If
to MannKind:
MannKind
Corporation
Attn:
General Counsel
30930
Russell Ranch Road, Suite 300
Westlake
Village, CA 91362
Email:
legal@mannkindcorp.com
If
to Pulmatrix:
Pulmatrix,
Inc.
Attn:
Ted Raad, CEO
945
Concord Street
Framingham
MA 01701
Email:
traad@pulmatrix.com
Section
9.3: Assignment.
The
Agreement shall be binding on the Parties and their successors and permitted assigns. Neither Party shall assign, transfer or delegate
any of its rights, duties or obligations under this Agreement, or any part thereof, whether by operation of law or otherwise, without
the prior written consent of the other Party, provided that either Party shall be entitled to assign or transfer this Agreement in connection
with the sale or acquisition of all or substantially all of its business to which this Agreement relates, whether by merger, sale of
stock, sale of assets or otherwise. Any assignment in violation of this paragraph shall be void ab initio.
Section
9.4: Publicity; Press Releases.
Except
as permitted pursuant to Section 7.4 or as otherwise required by applicable law, (a) neither Party shall, without the prior written
consent of the other Party which shall not be unreasonably withheld, issue any press releases or make any public statements concerning
the existence of or activities under this Agreement and (b) the Parties will mutually agree upon the content and timing of any press
release announcing the execution of this Agreement or otherwise relating to the terms of this Agreement.
Section
9.5: Modifications; Waiver.
This
Agreement may be modified only pursuant to a writing executed by authorized representatives of both Parties. The Parties expressly disclaim
the right to claim the enforceability of any oral modifications to this Agreement or any amendments based on course of dealing, waiver,
reliance, estoppel or other similar legal theory. No delay or omission by either Party to exercise any right occurring upon any non-compliance
or default of the other Party with respect to any of the terms of this Agreement shall impair any such right or be construed to be a
waiver thereof.
Section
9.6: No Third Party Beneficiaries.
This
Agreement is for the sole benefit of the Parties and their successors and permitted assigns and nothing herein, express or implied, shall
give or be construed to give any Person other than the Parties any legal or equitable rights hereunder.
Section
9.7: Severability.
In
the event any provision of this Agreement is determined by a court of competent jurisdiction to be invalid or unenforceable under applicable
law, such provision shall be amended and interpreted to accomplish the objectives of such provision to the greatest extent possible under
applicable law, and the remaining provisions of this Agreement shall continue in full force and effect.
Section
9.8: Governing Law.
This
Agreement shall be governed by and construed in accordance with the laws of Delaware, without reference to the principles of conflicts
of law that would apply the substantive laws of another jurisdiction. Notwithstanding the foregoing, nothing herein shall prevent either
Party from commencing an action for the purpose of seeking immediate injunctive relief in the appropriate jurisdiction.
Section
9.9: Survival.
Termination
or expiration of this Agreement shall not affect any rights or obligations of the Parties under this Agreement that have accrued prior
to the date of termination or expiration. Any provision of this Agreement that contemplates performance or observance subsequent to any
expiration or termination of this Agreement, or which is otherwise necessary to interpret the respective rights and obligations of the
Parties hereunder, shall survive any expiration or termination of this Agreement and continue in full force and effect, including without
limitation Section 4.1 (Term), Section 4.4 (Effects of Termination), Article 5 (Indemnification), Article 6
(Limitation of Liability), Article 7 (Confidentiality), and Article 9 (Additional Provisions).
Section
9.10: Headings; Construction.
The
headings of the various sections in this Agreement are for convenience of reference only and shall not affect the construction or interpretation
of this Agreement. The Parties acknowledge and agree that any principle of construction or rule of law that provides that an agreement
shall be construed against the drafter of the agreement in the event of any inconsistency or ambiguity in such agreement shall not apply
to the terms and conditions of this Agreement.
Section
9.11: Entire Agreement.
This
Agreement, together with the Schedules attached hereto, sets forth the entire and exclusive agreement between the Parties as to the subject
matter hereof and supersedes all prior and contemporaneous understandings, negotiations and agreements, written or oral, between the
Parties.
Section
9.12: Rights in Bankruptcy
(a)
The Parties intend to take advantage of the protections of Section 365(n) (or any successor provision) of the U.S. Bankruptcy Code or
any analogous provisions in any other country or jurisdiction to the maximum extent permitted by applicable law. All rights and licenses
granted under or pursuant to this Agreement, but only to the extent they constitute licenses of a right to “intellectual property”
as defined in Section 101 of the U.S. Bankruptcy Code or in any analogous provisions in any other country or jurisdiction (as the case
may be) shall be deemed to be “intellectual property” for the purposes of Section 365(n) or any analogous provisions in any
other country or jurisdiction (as the case may be). The Parties shall retain and may fully exercise all of their rights and elections
under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, including the right to obtain the intellectual
property from another entity.
(b)
During the Term, Licensor shall create and maintain current copies to the extent practicable of all such intellectual property. In the
event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions
in any other country or jurisdiction, the Party that is not subject to such proceeding shall be entitled to a complete duplicate of (or
complete access to, as appropriate) all such intellectual property (including all embodiments of such intellectual property), which,
if not already in the non-subject Party’s possession, shall be promptly delivered to it upon the non-subject Party’s written
request (a) after commencement of a bankruptcy proceeding, unless the Party subject to such proceeding continues to perform all of its
obligations under this Agreement, or (b) if not delivered pursuant to clause (a) above because the subject Party continues to perform,
upon the rejection of this Agreement by or on behalf of the subject Party.
(c)
All rights of the Parties under this Section 9.12 and under the U.S. Bankruptcy Code or any analogous provisions in any other
country or jurisdiction (as the case may be) are in addition to and not in substitution of any and all other rights, powers, and remedies
that each Party may have under this Agreement and any other applicable laws. If a case under the U.S. Bankruptcy Code or any analogous
provisions in any other country or jurisdiction (as the case may be) is commenced by or against Licensor, Licensee shall have the right
to perform the obligations of Licensor hereunder with respect to such intellectual property, but neither such provision nor such performance
by Licensee shall release Licensor from any such obligation or liability for failing to perform it.
(b)
The Parties agree that they intend the foregoing Licensee rights to extend to the maximum extent permitted by law and any provisions
of applicable contracts with Third Parties, including for purposes of the U.S. Bankruptcy Code or any analogous provisions in any other
country or jurisdiction (as the case may be), (i) the right of access to any intellectual property (including all embodiments thereof)
of Licensor or any Third Party with whom Licensor contracts to perform an obligation of Licensor under this Agreement, and, in the case
of the Third Party, which is necessary for the Exploitation of a product within the scope of the licenses granted to Licensee under this
Agreement and (ii) the right to contract directly with any Third Party described in (i) in this sentence to complete the contracted work.
Section
9.13: Counterparts.
This
Agreement may be executed in several counterparts, including by e-mail and with electronic signatures, each of which will be deemed an
original, and all of which taken together shall constitute one single agreement between the Parties with the same effect as if all the
signatures were upon the same instrument. An electronic signature shall be as legally effective as an original signature.
[SIGNATURE
PAGE FOLLOWS]
IN
WITNESS WHEREOF, the Parties have duly executed and delivered this Agreement as of the Effective Date.
| MANNKIND
CORPORATION |
|
| |
|
|
| By: |
/s/
Michael Castagna |
|
| Name: |
Michael
Castagna |
|
| Title: |
Chief
Executive Officer |
|
| |
|
|
| PULMATRIX,
INC. |
|
| |
|
|
| By: |
/s/
Teofilo Raad |
|
| Name: |
Teofilo
Raad |
|
| Title: |
Chief
Executive Officer |
|
Schedule
1
Pulmatrix
Licensed Technology
| Family
ID |
|
Patent
Application Title |
|
Country |
|
Application
Number |
|
Grant
Date |
|
Patent
No. |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
61/267747 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Patent
Cooperation Treaty |
|
PCT/US2010/028961 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS |
|
United
States of America |
|
61/387883 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
61/387925 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
61/431242 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS |
|
United
States of America |
|
61/481879 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
European
Patent |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
European
Patent |
|
10713283.9_OPP |
|
15-Mar-2017 |
|
2410981 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Patent
Cooperation Treaty |
|
PCT/US2011/049435 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Australia |
|
2010229668 |
|
08-Sep-2016 |
|
2010229668 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Brazil |
|
PI1011721-0 |
|
16-Nov-2021 |
|
PI1011721-0 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Canada |
|
2754691 |
|
30-Jul-2019 |
|
2754691 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
China |
|
201080023554.3 |
|
23-Mar-2018 |
|
ZL201080023554.3 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Russian
Federation |
|
2011137960 |
|
16-Feb-2016 |
|
2577698 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
India |
|
7373/DELNP/2011 |
|
08-Sep-2021 |
|
376685 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Israel |
|
215276 |
|
01-Dec-2016 |
|
215276 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Japan |
|
2012-502314 |
|
26-Dec-2014 |
|
5671001 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Korea,
Republic of (KR) |
|
10-2011-7024843 |
|
06-Jul-2016 |
|
10-1639098 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Mexico |
|
MX/a/2011/009957 |
|
22-Mar-2018 |
|
354829 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
New
Zealand |
|
595281 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
13/259635 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Patent
Cooperation Treaty |
|
PCT/US2011/053829 |
|
|
|
|
| PUL121 |
|
PROCESSABLE
DRY POWDERS |
|
United
States of America |
|
61/605083 |
|
|
|
|
| PUL121 |
|
PROCESSABLE
DRY POWDERS |
|
United
States of America |
|
61/607928 |
|
|
|
|
| PUL121 |
|
PROCESSABLE
DRY POWDERS |
|
United
States of America |
|
61/645927 |
|
|
|
|
| PUL121 |
|
PROCESSABLE
DRY POWDERS |
|
United
States of America |
|
61/648506 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Hong
Kong |
|
12106373.0 |
|
05-Jan-2018 |
|
1165709 |
| PUL121 |
|
PROCESSABLE
DRY POWDERS |
|
United
States of America |
|
61/707071 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Australia |
|
2011296343 |
|
23-Mar-2016 |
|
2011296343 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Canada |
|
2809666 |
|
22-Sep-2020 |
|
2809666 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
China |
|
201180052479.8 |
|
31-Jul-2018 |
|
ZL201180052479.8 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
European
Patent |
|
11751775.5 |
|
01-Apr-2020 |
|
2611438 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Israel |
|
224916 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Japan |
|
2013-527146 |
|
29-Jan-2016 |
|
5877201 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
New
Zealand |
|
607749 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
13/817963 |
|
23-Jun-2015 |
|
9061352 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Australia |
|
2011308865 |
|
20-Apr-2017 |
|
2011308865 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS |
|
Brazil |
|
BR112013007304-7 |
|
14-Dec-2021 |
|
BR112013007304-7 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Canada |
|
2812414 |
|
22-Sep-2020 |
|
2812414 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
China |
|
201180057314.X |
|
05-Apr-2017 |
|
ZL201180057314.X |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
European
Patent |
|
11770941.0 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Israel |
|
225398 |
|
01-Apr-2018 |
|
225398 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
India |
|
2755/DELNP/2013 |
|
24-Sep-2019 |
|
321221 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Japan |
|
2013-531826 |
|
29-Jan-2016 |
|
5877204 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Korea,
Republic of (KR) |
|
10-2013-7010157 |
|
30-Oct-2018 |
|
101915241 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Mexico |
|
MX/a/2013/003478 |
|
22-Mar-2018 |
|
354828 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
New
Zealand |
|
608834 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Russian
Federation |
|
2013118453 |
|
12-Jan-2018 |
|
2640921 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
13/876312 |
|
09-May-2017 |
|
9642798 |
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
Patent
Cooperation Treaty |
|
PCT/US2013/028261 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
New
Zealand |
|
621065 |
|
03-Nov-2015 |
|
621065 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Hong
Kong |
|
13114302.9 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Hong
Kong |
|
14100210.8 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
14/456445 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
United
States of America |
|
14/378453 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
European
Patent |
|
13709666.5 |
|
|
|
|
| PUL121 |
|
PROCESSABLE
DRY POWDERS |
|
Japan |
|
2014-560032 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
China |
|
201380020063.7 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
Australia |
|
2013225982 |
|
15-Mar-2018 |
|
2013225982 |
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
Canada |
|
2865972 |
|
04-Jan-2022 |
|
2865972 |
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
Israel |
|
234153 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
India |
|
6933/DELNP/2014 |
|
04-Dec-2020 |
|
353032 |
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
New
Zealand |
|
629722 |
|
04-Jul-2017 |
|
629722 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
New
Zealand |
|
705080 |
|
01-Nov-2016 |
|
705080 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
New
Zealand |
|
703804 |
|
30-Aug-2016 |
|
703804 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Japan |
|
2014-256325 |
|
08-Jul-2016 |
|
5964939 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
14/666959 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
14/667857 |
|
01-Sep-2015 |
|
9119778 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
14/717243 |
|
12-Jan-2016 |
|
9233158 |
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
Hong
Kong |
|
15105912.7 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
14/804940 |
|
19-Jan-2016 |
|
9238005 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
14/960695 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
14/954128 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
China |
|
201610054941.2 |
|
16-Aug-2019 |
|
ZL201610054941.2 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Japan |
|
2016-011411 |
|
04-Aug-2017 |
|
6186458 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/095586 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Israel |
|
|
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/095319 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
European
Patent |
|
17000124.2 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/245656 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/247040 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
15/277062 |
|
13-Aug-2019 |
|
10376465 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Australia |
|
2016269398 |
|
17-Jan-2019 |
|
2016269398 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/401215 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/401303 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
China |
|
201710140007.7 |
|
15-Jul-2022 |
|
ZL201710140007.7 |
| PUL121 |
|
METHODS
FOR PRODUCING RESPIRABLE DRY POWDERS |
|
United
States of America |
|
15/495450 |
|
17-Mar-2020 |
|
10589039 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/601669 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/602724 |
|
|
|
|
| PUL121 |
|
PROCESSABLE
DRY POWDERS |
|
Japan |
|
2017-104816 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
China |
|
201710695234.6 |
|
23-Apr-2021 |
|
ZL201710695234.6 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Japan |
|
2017-148309 |
|
31-Aug-2018 |
|
6392422 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/720690 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/720445 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Israel |
|
256360 |
|
01-Jul-2020 |
|
256360 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Hong
Kong |
|
17113613.1 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Russian
Federation |
|
2017144619 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
China |
|
201810147094.3 |
|
19-Nov-2021 |
|
ZL201810147094.3 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/897274 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
15/897345 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Mexico |
|
MX/a/2018/002638 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Belgium |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Switzerland |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Germany
(Federal Republic of) |
|
10713283.9 |
|
15-Mar-2017 |
|
602010040750.0 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Denmark |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Spain |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
Kingdom |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Ireland
(Republic of) |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Netherlands |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Norway |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Portugal |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Sweden |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
France |
|
10713283.9 |
|
15-Mar-2017 |
|
2410981 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/039547 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/036226 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Korea,
Republic of (KR) |
|
10-2018-7031481 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/202422 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/202457 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
China |
|
201910141714.7 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/389178 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/389065 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS |
|
United
States of America |
|
16/456990 |
|
|
|
|
| PUL121 |
|
PROCESSABLE
DRY POWDERS |
|
Japan |
|
2019-128556 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/559096 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/562027 |
|
|
|
|
| PUL115 |
|
A
RESPIRABLE DRY POWDER |
|
India |
|
201918037611 |
|
|
|
|
| PUL115 |
|
A
RESPIRABLE DRY POWDER COMPRISING RESPIRABLE DRY PARTICLES |
|
India |
|
201918037610 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Israel |
|
271976 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
United
States of America |
|
16/752841 |
|
20-Oct-2020 |
|
10806871 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/781744 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/781704 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
Kingdom |
|
11751775.5 |
|
01-Apr-2020 |
|
2611438 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
Germany
(Federal Republic of) |
|
11751775.5 |
|
01-Apr-2020 |
|
602011065994.4 |
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
France |
|
11751775.5 |
|
01-Apr-2020 |
|
2611438 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Canada |
|
3086367 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/908964 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
16/914999 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
United
States of America |
|
17/021709 |
|
01-Feb-2022 |
|
11235112 |
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/086515 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/097018 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
United
States of America |
|
63/156111 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDER FOR INHALATION |
|
United
States of America |
|
17/134827 |
|
16-Nov-2021 |
|
11173115 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Canada |
|
|
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/225362 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/221263 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/459027 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/402147 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
17/494241 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/555556 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
Patent
Cooperation Treaty |
|
PCT/US2022/018306 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/570656 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Israel |
|
286573 |
|
03-Nov-2022 |
|
286573 |
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
European
Patent |
|
21207551.9 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
United
States of America |
|
17/550185 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
17/674898 |
|
|
|
|
| PUL121 |
|
US_PUL121CON5_INHALABLE
DRY POWDERS |
|
United
States of America |
|
17/724714 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/735514 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Russian
Federation |
|
2022101759 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/747306 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
17/848610 |
|
|
|
|
| PUL156 |
|
METHODS
FOR TREATING CANCER USING INHALED ANGIOGENESIS INHIBITOR |
|
United
States of America |
|
63/399080 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
United
States of America |
|
17/895963 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/941202 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
17/950188 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
18/050584 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
United
States of America |
|
18/153041 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
18/160011 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
18/163922 |
|
|
|
|
| PUL115 |
|
PUL-115EPDIV_MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Hong
Kong |
|
42022065329.9 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
United
States of America |
|
18/335544 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
18/342136 |
|
|
|
|
| PUL117 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
|
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
18/194641 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
18/348265 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
18/454289 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
18/400030 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
United
States of America |
|
18/663609 |
|
|
|
|
| PUL115 |
|
MONOVALENT
METAL CATION DRY POWDERS FOR INHALATION |
|
Mexico |
|
MX/a/2023/008323 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
United
States of America |
|
18/502674 |
|
|
|
|
| PUL121 |
|
INHALABLE
DRY POWDERS |
|
United
States of America |
|
18/611131 |
|
|
|
|
| PUL156 |
|
METHODS
FOR TREATING CANCER USING INHALED ANGIOGENESIS INHIBITOR |
|
Patent
Cooperation Treaty |
|
PCT/US2023/072395 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
18/515615 |
|
|
|
|
| PUL109 |
|
DRY
POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES |
|
United
States of America |
|
18/626633 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
Australia |
|
2022228443 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
Brazil |
|
BR112023017538-0 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
Canada |
|
3210442 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
China |
|
202280031563.X |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
European
Patent |
|
22710901.4 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
Israel |
|
305506 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
India |
|
202317062881 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
Japan |
|
2023-553124 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
Korea,
Republic of (KR) |
|
10-2023-7032645 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
Mexico |
|
MX/a/2023/010120 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
New
Zealand |
|
803263 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
Russian
Federation |
|
2023122682 |
|
|
|
|
| PUL155 |
|
DIHYDROERGOTAMINE
DRY POWDER FORMULATIONS AND METHODS OF USE |
|
United
States of America |
|
18/548896 |
|
|
|
|
| PUL114 |
|
RESPIRABLY
DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE |
|
United
States of America |
|
13/504284 |
|
|
|
8758824 |
| PUL114 |
|
RESPIRABLY
DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE |
|
Hong
Kong |
|
12111251.7 |
|
|
|
|
| PUL114 |
|
RESPIRABLY
DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE |
|
Switzerland |
|
11757713.0 |
|
|
|
2448571 |
| PUL114 |
|
RESPIRABLY
DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE |
|
Germany |
|
11757713.0 |
|
|
|
602011002018.8 |
| PUL114 |
|
RESPIRABLY
DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE |
|
France |
|
11757713.0 |
|
|
|
2448571 |
| PUL114 |
|
RESPIRABLY
DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE |
|
Sweden |
|
11757713.0 |
|
|
|
2448571 |
| PUL114 |
|
RESPIRABLY
DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE |
|
United
Kingdom |
|
11757713.0 |
|
|
|
2448571 |
| PUL114 |
|
RESPIRABLY
DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE |
|
United
States of America |
|
14/284880 |
|
|
|
8992983 |
| PUL114 |
|
RESPIRABLY
DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE |
|
United
States of America |
|
14/633432 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
61/387855 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Patent
Cooperation Treaty |
|
PCT/US2011/053833 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Australia |
|
2011314007 |
|
04-May-2017 |
|
2011314007 |
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Canada |
|
2812417 |
|
22-Oct-2019 |
|
2812417 |
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
European
Patent |
|
11767877.1 |
|
07-Nov-2018 |
|
2621488 |
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Israel |
|
225399 |
|
28-May-2020 |
|
225399 |
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
New
Zealand |
|
608838 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
13/876315 |
|
06-Sep-2016 |
|
9433576 |
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
15/220732 |
|
29-Aug-2017 |
|
9744130 |
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
15/650255 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
15/819749 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
15/958101 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
16/129278 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Belgium |
|
11767877.1 |
|
07-Nov-2018 |
|
2621488 |
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Switzerland |
|
11767877.1 |
|
07-Nov-2018 |
|
2621488 |
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Germany |
|
11767877.1 |
|
07-Nov-2018 |
|
602011053653.2 |
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Denmark |
|
11767877.1 |
|
07-Nov-2018 |
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
France |
|
11767877.1 |
|
07-Nov-2018 |
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
Kingdom |
|
11767877.1 |
|
07-Nov-2018 |
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Ireland |
|
11767877.1 |
|
07-Nov-2018 |
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Netherlands |
|
11767877.1 |
|
07-Nov-2018 |
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Norway |
|
11767877.1 |
|
07-Nov-2018 |
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Sweden |
|
11767877.1 |
|
07-Nov-2018 |
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Spain |
|
11767877.1 |
|
07-Nov-2018 |
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
Portugal |
|
11767877.1 |
|
07-Nov-2018 |
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
16/272045 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
16/455350 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
16/675956 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
16/837541 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
17/003172 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
17/140602 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
17/349449 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
17/513289 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
17/693336 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
17/866848 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
18/061214 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
18/303612 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
18/464491 |
|
|
|
|
| PUL116 |
|
CATIONIC
DRY POWDERS |
|
United
States of America |
|
18/413779 |
|
|
|
|
Schedule
2
MannKind
Licensed Technology
| MANNKIND REF. |
|
ATTORNEY
Ref. |
|
Country |
|
Serial
# |
|
File
Date |
|
Patent
# |
|
Issue Date |
|
Status |
|
Exp.
Date |
| A
DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY |
| 51300-00074-AR |
|
51300-00074-AR |
|
ARGENTINA |
|
P-090102125 |
|
6/12/2009 |
|
AR072114B1 |
|
9/15/2016 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-AR-1 |
|
51300-00074.1AR |
|
ARGENTINA |
|
20160100755 |
|
3/21/2016 |
|
AR104034B2 |
|
7/29/2021 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-AR-2 |
|
51300-00074.2 |
|
ARGENTINA |
|
20160100756 |
|
3/21/2016 |
|
AR104035B2 |
|
9/29/2023 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-AU |
|
51300-00074-AU |
|
AUSTRALIA |
|
2009257311 |
|
6/12/2009 |
|
2009257311 |
|
3/19/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-AU-1 |
|
51300-00074.1-
AU |
|
AUSTRALIA |
|
2014200952 |
|
2/24/2014 |
|
2014200952 |
|
3/26/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-AU-2 |
|
51300-00074.2-AU |
|
AUSTRALIA |
|
2014200982 |
|
2/24/2014 |
|
2014200982 |
|
1/14/2016 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-AU-3 |
|
51300-00074.3-AU |
|
AUSTRALIA |
|
2014200975 |
|
2/24/2014 |
|
2014200975 |
|
5/21/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-AU-4 |
|
51300-00074.4-AU |
|
AUSTRALIA |
|
2015200947 |
|
6/12/2009 |
|
2015200947 |
|
8/24/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-BR |
|
51300-00074-BR |
|
BRAZIL |
|
PI0914998-8 |
|
6/12/2009 |
|
PI09149988 |
|
8/3/2021 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-CA |
|
51300-00074-CA |
|
CANADA |
|
2728230 |
|
6/12/2009 |
|
2728230 |
|
10/17/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-CA-1 |
|
51300.00325
CA DIV |
|
CANADA |
|
2982550 |
|
6/12/2009 |
|
2982550 |
|
8/25/2020 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-CA-2 |
|
51300.00424
CA |
|
CANADA |
|
3086027 |
|
6/12/2009 |
|
3086027 |
|
5/17/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-CA-3 |
|
51300.00466 |
|
CANADA |
|
3153292 |
|
6/12/2009 |
|
|
|
|
|
PENDING |
|
6/12/2029 |
| 51300-00074-CN-1 |
|
51300.00074.1
CN |
|
CHINA |
|
200980000440.4 |
|
6/12/2009 |
|
CN101827626B |
|
3/18/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-CN-3 |
|
51300-000175-CN |
|
CHINA |
|
201410612764.6 |
|
6/12/2009 |
|
104491962 |
|
10/23/2018 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-CN-4 |
|
51300.00074.3
CN |
|
CHINA |
|
201510084945.0 |
|
6/12/2009 |
|
104689432 |
|
7/6/2018 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-EP-1 |
|
51300-00074-EPDIV1 |
|
EUROPE |
|
12170549.5
(EP 2570147) |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
VALIDATED |
|
6/12/2029 |
| 51300-00074-BE-1 |
|
51300-00074-BE-1 |
|
BELGIUM |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-DE-1 |
|
51300-00074-DE-1 |
|
GERMANY |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-DK-1 |
|
51300-00074-DK-1 |
|
DENMARK |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-ES-1 |
|
51300-00074-ES-1 |
|
SPAIN |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-FR-1 |
|
51300-00074-FR-1 |
|
FRANCE |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-GB-1 |
|
51300-00074-GB-1 |
|
UNITED
KINGDOM |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-IE-1 |
|
51300-00074-IE-1 |
|
IRELAND |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-IT-1 |
|
51300-00074-IT-1 |
|
ITALY |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-LI-1 |
|
51300-00074-LI-1 |
|
LIECHTENSTEIN |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-LU-1 |
|
51300-00074-LU-1 |
|
LUXEMBOURG |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-NL-1 |
|
51300-00074-NL-1 |
|
NETHERLANDS |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-CH-1 |
|
51300-00074-CH-1 |
|
SWITZERLAND |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-SE-1 |
|
51300-00074-SE-1 |
|
SWEDEN |
|
12170549.5 |
|
6/1/2012 |
|
2570147 |
|
10/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-EP-2 |
|
51300-00074-EPDIV2 |
|
EUROPE |
|
EP12170583.4 |
|
6/1/2012 |
|
2567723 |
|
1/20/2021 |
|
VALIDATED |
|
6/12/2029 |
| 51300-00074-DE-2 |
|
51300-00074-DE-2 |
|
GERMANY |
|
EP12170583.4 |
|
6/1/2012 |
|
2567723 |
|
1/20/2021 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-FR-2 |
|
51300-00074-FR-2 |
|
FRANCE |
|
EP12170583.4 |
|
6/1/2012 |
|
2567723 |
|
1/20/2021 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-GB-2 |
|
51300-00074-GB-2 |
|
UNITED
KINGDOM |
|
EP12170583.4 |
|
6/1/2012 |
|
2567723 |
|
1/20/2021 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-EP-3 |
|
1951300.00323EPDIV |
|
EUROPE |
|
17191023.5 |
|
9/14/2017 |
|
3281663 |
|
8/17/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-DE-3 |
|
1951300.00323DEDIV |
|
GERMANY |
|
17191023.5 |
|
9/14/2017 |
|
3281663 |
|
8/17/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-FR-3 |
|
1951300.00323FRDIV |
|
FRANCE |
|
17191023.5 |
|
9/14/2017 |
|
3281663 |
|
8/17/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-ES-3 |
|
1951300.00323ESDIV |
|
SPAIN |
|
17191023.5 |
|
9/14/2017 |
|
3281663 |
|
8/17/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-IT-3 |
|
1951300.00323ITDIV |
|
ITALY |
|
17191023.5 |
|
9/14/2017 |
|
3281663 |
|
8/17/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-CH-3 |
|
1951300.00323CHDIV |
|
SWITZERLAND |
|
17191023.5 |
|
9/14/2017 |
|
3281663 |
|
8/17/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-NL-3 |
|
1951300.00323NLDIV |
|
NETHERLANDS |
|
17191023.5 |
|
9/14/2017 |
|
3281663 |
|
8/17/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-GB-3 |
|
1951300.00323GBDIV |
|
UNITED
KINGDOM |
|
17191023.5 |
|
9/14/2017 |
|
3281663 |
|
8/17/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-HK-3-EP2 |
|
51300-00074.2HK |
|
HONG
KONG |
|
13110557.9 |
|
6/12/2009 |
|
HK1183251 |
|
5/7/2021 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-HK-CN1 |
|
51300-00074-1-HK |
|
Hong
Kong |
|
11101802.3 |
|
2/24/2011 |
|
HK1147706 |
|
1/13/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-HK-4-CN3 |
|
51300-00175-HK |
|
HONG
KONG |
|
15109097.6 |
|
10/27/2015 |
|
HK1209665 |
|
7/12/2019 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-HK-4-CN4 |
|
51300-00074.3HK |
|
HONG
KONG |
|
15110536.3 |
|
9/17/2015 |
|
HK1208389 |
|
10/4/2019 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-HK-6-EP3 |
|
51300.00370
HK |
|
HONG
KONG |
|
18108979.8 |
|
6/12/2009 |
|
HK1249463 |
|
12/30/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-ID |
|
51300-00074-ID |
|
INDONESIA |
|
W00201100149 |
|
6/12/2009 |
|
ID
P 0034130 |
|
7/12/2013 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-IL |
|
51300-00074-IL |
|
ISRAEL |
|
209956 |
|
6/12/2009 |
|
209956 |
|
12/31/2014 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-IL-1 |
|
51300-00074.1-IL |
|
ISRAEL |
|
227046 |
|
6/12/2009 |
|
227046 |
|
11/1/2016 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-IL-2 |
|
51300-000152IL |
|
ISRAEL |
|
234322 |
|
6/12/2009 |
|
234322 |
|
8/30/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-IL-3 |
|
5130000074.2IL |
|
ISRAEL |
|
246442 |
|
6/12/2009 |
|
246442 |
|
6/30/2018 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-IL-6 |
|
51300.00495-IL |
|
ISRAEL |
|
303019 |
|
5/18/2023 |
|
|
|
|
|
PENDING |
|
6/12/2029 |
| 51300-00074-IN |
|
51300-00074-IN |
|
INDIA |
|
252/DELNP/2011 |
|
6/12/2009 |
|
280564 |
|
2/22/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-IN-1 |
|
51300-00074.1-IN |
|
INDIA |
|
201618038349 |
|
6/12/2009 |
|
422785 |
|
2/22/2023 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-JP-1 |
|
51300-00074.1-JP |
|
JAPAN |
|
2013-241130 |
|
11/28/2013 |
|
5839732 |
|
11/20/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-JP-2 |
|
51300-00074.2-JP |
|
JAPAN |
|
2015-038046 |
|
2/27/2015 |
|
|
|
|
|
PENDING |
|
6/12/2029 |
| 51300-00074-KR |
|
51300-00074-KR |
|
SOUTH
KOREA |
|
10-2011-7000330 |
|
6/12/2009 |
|
1558026 |
|
9/30/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-KR-1 |
|
51300-00153-KR.2 |
|
SOUTH
KOREA |
|
10-2014-7026936 |
|
9/25/2014 |
|
1548092 |
|
8/21/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-KR-2 |
|
51300-00154-KR.3 |
|
SOUTH
KOREA |
|
10-2014-7026937 |
|
9/25/2014 |
|
1591621 |
|
1/28/2016 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-KR-3 |
|
51300-00153KR.1 |
|
SOUTH
KOREA |
|
10-2015-7007318 |
|
3/23/2015 |
|
1655053 |
|
8/31/2016 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-KR-4 |
|
51300.00074.1KR |
|
SOUTH
KOREA |
|
10-2015-0077234 |
|
6/1/2015 |
|
1618515 |
|
4/28/2016 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-KR-5 |
|
51300-00154.1KR |
|
SOUTH
KOREA |
|
10-2015-0077266 |
|
6/1/2015 |
|
1655032 |
|
8/31/2016 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-MX |
|
51300-00074-MX |
|
MEXICO |
|
MX/a/2010/013590 |
|
6/12/2009 |
|
333045 |
|
9/8/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-MX-1 |
|
51300-00074-MX-DIV |
|
MEXICO |
|
MX/a/2015/011834 |
|
9/7/2015 |
|
395141 |
|
8/29/2022 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-MY |
|
51300-00074-MY |
|
MALAYSIA |
|
2010005946 |
|
6/12/2009 |
|
MY
1555524-A |
|
10/30/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-MY-1 |
|
51300-00074.1
MY |
|
MALAYSIA |
|
PI2014002366 |
|
8/14/2014 |
|
MY
172371-A |
|
11/21/2019 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-MY-2 |
|
51300-00074.2
MY |
|
MALAYSIA |
|
PI2014002367 |
|
8/14/2014 |
|
MY-176697-A |
|
08/19/2020 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-RU |
|
51300-00074-RU |
|
RUSSIA |
|
2011100779 |
|
6/12/2009 |
|
2468832 |
|
12/10/2012 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-RU-1 |
|
51300-00074-RU1 |
|
RUSSIA |
|
2012136220 |
|
6/12/2009 |
|
2608439 |
|
1/18/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-RU-2 |
|
51300-00074DIV2 |
|
RUSSIA |
|
2016147947 |
|
12/7/2016 |
|
2731107 |
|
8/28/2020 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-SG |
|
51300-00074-SG |
|
SINGAPORE |
|
2010092534.0 |
|
6/12/2009 |
|
167365 |
|
9/4/2015 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-SG-1 |
|
51300-00074-SG
DIV1 |
|
SINGAPORE |
|
10201507036T |
|
6/12/2009 |
|
10201507036T |
|
6/17/2021 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-SG-2 |
|
51300-00074-SG
DIV2 |
|
SINGAPORE |
|
10201507038V |
|
6/12/2009 |
|
10201507038V |
|
6/17/2021 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-TW |
|
51300-00074-TW |
|
TAIWAN |
|
98119686 |
|
6/12/2009 |
|
I592178 |
|
7/21/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-TW-1 |
|
51300-00074.1TW |
|
TAIWAN |
|
104124899 |
|
6/12/2009 |
|
I611818 |
|
1/21/2018 |
|
ISSUED |
|
6/12/2029 |
| 51300-00074-US-8 |
|
51300.00458
US |
|
UNITED
STATES |
|
17/512,529 |
|
10/27/2021 |
|
|
|
|
|
PENDING |
|
|
| 51300-00074-WO |
|
51300-00074-WO |
|
WIPO |
|
PCT/US2009/047281 |
|
6/12/2009 |
|
WO
09/152477 |
|
12/17/2009 |
|
NAT
PHASE |
|
____ |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| A
DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY |
| 51300-00103-US |
|
51300.00103-US |
|
UNITED
STATES |
|
12/484,125 |
|
6/12/2009 |
|
8,499,757 |
|
8/6/2013 |
|
ISSUED |
|
2/19/2032 |
| 51300-00103-US-5 |
|
51300.00459 |
|
UNITED
STATES |
|
TBA |
|
|
|
|
|
|
|
PENDING |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| A
DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY |
| 51300-00106-US |
|
51300.00106-US |
|
UNITED
STATES |
|
12/484,129 |
|
6/12/2009 |
|
8,636,001 |
|
1/28/2014 |
|
ISSUED |
|
7/12/2032 |
| 51300-00106-US-4 |
|
51300-00106.3-US |
|
UNITED
STATES |
|
14/092,810 |
|
11/27/2013 |
|
9,511,198 |
|
12/6/2016 |
|
ISSUED |
|
2/16/2030 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DRY
POWDER DELIVERY SYSTEM AND METHODS |
| 51300-00124-AU |
|
51300.00124AU |
|
AUSTRALIA |
|
2011271097 |
|
6/21/2011 |
|
2011271097.0 |
|
3/12/2015 |
|
ISSUED |
|
6/21/2031 |
| 51300.00124-AU-1 |
|
51300.00124.1AU |
|
AUSTRALIA |
|
2015200705 |
|
6/21/2011 |
|
2015200705 |
|
9/29/2016 |
|
ISSUED |
|
6/21/2031 |
| 51300-00124-AU-2 |
|
51300.00124.2AU |
|
AUSTRALIA |
|
2016222336 |
|
8/30/2016 |
|
2016222336 |
|
1/3/2019 |
|
ISSUED |
|
6/21/2031 |
| 51300-00124-CA |
|
51300.00124CA |
|
CANADA |
|
2801936 |
|
6/21/2011 |
|
2801936 |
|
6/1/2021 |
|
ISSUED |
|
6/21/2031 |
| 51300-00124-IL |
|
51300.00124IL |
|
ISRAEL |
|
223742 |
|
6/21/2011 |
|
223742 |
|
10/1/2016 |
|
ISSUED |
|
6/21/2031 |
| 51300-00124-IN |
|
51300.00124IN |
|
INDIA |
|
10855/DELNP/2012 |
|
6/21/2011 |
|
313526 |
|
5/31/2019 |
|
ISSUED |
|
6/21/2031 |
| 51300-00124-JP |
|
51300.00124JP |
|
JAPAN |
|
2013516701 |
|
6/21/2011 |
|
6385673 |
|
8/17/2018 |
|
ISSUED |
|
6/21/2031 |
| 51300-00124-MX |
|
51300.00124MX |
|
MEXICO |
|
MX/a/2012/015093 |
|
6/21/2011 |
|
359281 |
|
9/21/2018 |
|
ISSUED |
|
6/21/2031 |
| 51300-00124-RU |
|
51300.00124RU |
|
RUSSIA |
|
2013102529 |
|
6/21/2011 |
|
2531455 |
|
10/20/2014 |
|
ISSUED |
|
6/21/2031 |
| 51300-00124-RU-1 |
|
51300.00124-1
RU |
|
RUSSIA |
|
2014133362 |
|
6/21/2011 |
|
2571331 |
|
12/20/2015 |
|
ISSUED |
|
6/21/2031 |
| 51300-00124-US-3 |
|
51300.00249-2
(124) |
|
UNITED
STATES |
|
15/144,651 |
|
5/2/2016 |
|
9,662,461 |
|
5/30/2017 |
|
ISSUED |
|
6/12/2029 |
| 51300-00124-WO |
|
51300.00124WO |
|
WIPO |
|
PCT/US2011/041303 |
|
6/21/2011 |
|
WO
11/163272 |
|
12/29/2011 |
|
NAT
PHASE |
|
____ |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DRY
POWDER INHALER |
| 51300-00136-AR |
|
51300.00136AR |
|
ARGENTINA |
|
83811 |
|
4/20/2012 |
|
83811 |
|
4/20/2012 |
|
ISSUED |
|
4/20/2027 |
| 51300-00136-BR |
|
51300.00136BR |
|
BRAZIL |
|
BR3020120019982 |
|
4/20/2012 |
|
BR3020120019982 |
|
2/13/2013 |
|
ISSUED |
|
4/20/2037 |
| 51300-00136-EM |
|
51300.00136EM |
|
EUROPE
(CTM) |
|
002030130-0001 |
|
4/20/2012 |
|
002030130-0001 |
|
7/4/2012 |
|
ISSUED |
|
4/20/2037 |
| 51300-00136-GB |
|
51300.00136GB |
|
UNITED
KINGDOM |
|
9002030130-0001 |
|
4/20/2012 |
|
9002030130-0001 |
|
7/4/2012 |
|
ISSUED |
|
4/20/2037 |
| 51300-00136-IN |
|
51300.00136IN |
|
INDIA |
|
244714 |
|
4/20/2012 |
|
244714 |
|
8/23/2012 |
|
ISSUED |
|
10/20/2026 |
| 51300-00136-JP |
|
51300.00136JP |
|
JAPAN |
|
2012-009290 |
|
4/20/2012 |
|
1450065 |
|
8/3/2012 |
|
ISSUED |
|
8/3/2032 |
| 51300-00136-KR |
|
51300.00136KR |
|
SOUTH
KOREA |
|
30-2012-0018808 |
|
4/20/2012 |
|
30-0709561 |
|
9/13/2013 |
|
ISSUED |
|
9/13/2028 |
| 51300-00136-MX |
|
51300.00136MX |
|
MEXICO |
|
MX/f/2012/001228 |
|
4/20/2012 |
|
38664 |
|
5/10/2013 |
|
ISSUED |
|
4/20/2027 |
| 51300-00136-RU |
|
51300.00136RU |
|
RUSSIA |
|
2012501242 |
|
4/20/2012 |
|
84747 |
|
3/16/2013 |
|
ISSUED |
|
4/20/2037 |
| 51300-00136-TW |
|
51300.00136TW |
|
TAIWAN |
|
101302196 |
|
4/20/2012 |
|
D152925 |
|
4/11/2013 |
|
ISSUED |
|
4/20/2024 |
| 51300-00136-TW-1 |
|
51300.00136.1TW |
|
TAIWAN |
|
102300650 |
|
1/24/2013 |
|
D160905 |
|
6/1/2014 |
|
ISSUED |
|
4/20/2024 |
| 51300-00136-US |
|
51300.00136.US |
|
UNITED
STATES |
|
29/404,464 |
|
10/20/2011 |
|
D674,893 |
|
1/22/2013 |
|
ISSUED |
|
1/22/2027 |
